Design of a Phase III immunogenicity and safety study evaluating two-dose regimens of 9-valent human papillomavirus (9vHPV) vaccine with extended dosing intervals.
Sign Up to like & getrecommendations! Published in 2021 at "Contemporary clinical trials"
DOI: 10.1016/j.cct.2021.106403
Abstract: HPV vaccines are widely licensed as two-dose regimens, 6-12 months apart, for adolescents. Extended intervals between doses may be necessary due to resource constraints or vaccination program disruption. This international, multicenter, open-label study (NCT04708041) will evaluate… read more here.
Keywords: two dose; study; dose regimens; 9vhpv vaccine ... See more keywords
Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-up
Sign Up to like & getrecommendations! Published in 2020 at "Papillomavirus Research"
DOI: 10.1016/j.pvr.2020.100203
Abstract: Background The nine-valent human papillomavirus (9vHPV) vaccine protects against infection and disease related to HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58. The pivotal 36-month Phase III immunogenicity study of 9vHPV… read more here.
Keywords: immunogenicity; girls boys; analysis; 9vhpv vaccine ... See more keywords